VP of People Operations - Juno Therapeutics

VP of People Operations - Juno Therapeutics

August 17, 2017
August 17, 2017
 
 

Job Summary

COMPANY OVERVIEW

Established in 2013, Juno Therapeutics is on a quest to radically change the course of medicine.  Using a cancer patient’s own T cells, Juno’s investigational treatments harness the power of a patient’s own immune system to treat cancer and other serious diseases. 

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. Raising one of the largest Series A investments in biotech history, with total investments of $310m, Juno made an initial public offering in December 2014.

In preparation for the anticipated commercialization of their CAR-T therapy in 2018, Juno has grown to 600 employees, and will hire another 400 in the next year, doubling over that again in the next two years. 

ROLE OVERVIEW

As the COO of the People team, you will own and lead operations to include systems/tools/automation, people and recruiting operations, training & development, employee experience and analytics.  The best candidate for the role will be obsessed with staying one step ahead of making life at Juno productive, engaging, friction-free, so employees can focus on curing cancer! 

Quick Facts

Location:Seattle
Alternate Location:San Francisco
Job Family:Human Resources
Years of Experience:15+
Reporting to:SVP, People
Company Founded:2013
Company IPO:2014
Current # Employees:600
Planned # Employees:2000

More Info

Highlights30

Juno Therapeutics
 
founded2013
Hans Bishop
Business Executive, CEO
Herd Freed Hartz
Company, Executive Search Firm
Seattle
City in Washington

Photos - Company Photos22

Juno Therapeutics

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[2] The company raised $300 million through private funding and a further $265 million through their IPO.

Biotechnology

Biotechnology is the use of living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use" (UN Convention on Biological Diversity, Art. 2).[1] Depending on the tools and applications, it often overlaps with the (related) fields of bioengineering, biomedical engineering, biomanufacturing, molecular engineering, etc.

For thousands of years, humankind has used biotechnology in agriculture, food production, and medicine.[2] The term is largely believed to have been coined in 1919 by Hungarian engineer Károly Ereky. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests.[2]

Job Documents2

 

Company Info - Targeted Diseases6

Company Info - Therapies5

Company Info - Key Partners7

Videos142

News Articles8

ASH: CLLS Readying For CALM, IMDZ Awaits Data, Can JUNO Magic Continue?
  –  December 3, 2017
On December 9, 2017, preliminary results from two phase I trials with UCART19 ... (Source: Clinical Cancer Research) IMDZ closed Friday's trading at $4.20, up 2.44%. Shares of Juno Therapeutics Inc. (JUNO) have climbed an impressive 200% so far this ...
The Most Promising Cancer Treatments In a Century Have Arrived—But Not For Everyone
  –  November 29, 2017
The results were ... candidates in the pipeline. While Kite and Novartis were the only companies to actually launch products in 2017, more than 40 other pharma firms and startups are currently building pipelines. Chief rival Juno Therapeutics went public ...
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
  –  November 27, 2017
Juno Therapeutics (NASDAQ: JUNO) stock has soared so far in 2017, partially due to its own good fortunes, but also moving upwards as other CAR-T developers have experienced success. Juno announced its third-quarter results after the market closed on Wednesday.
Celgene (CELG) Announces Results from 282 Abstracts Including its Therapies and Pipeline Compounds to Be Presented at ASH
  –  November 21, 2017
We are also excited about results from novel technologies such as CAR-T cell therapy and other pipeline candidates across multiple ... from the CAR-T program JCAR-017 in partnership with Juno Therapeutics will be presented in multiple studies: Abstract ...
Editas Medicine Announces Third Quarter 2017 Results and Update
  –  November 7, 2017
Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ... pursuant to our collaboration with Juno Therapeutics, Inc., partially offset by a $0.4 ...
Global CAR T-cell Therapy for Multiple Myeloma Pipeline Analysis Report 2017
  –  November 3, 2017
The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical ... 12,590 deaths occur due to this disease in the US. Major companies Juno Therapeutics Kite Pharma Novartis Collectis Key Topics Covered: Part 01: Executive ...
Significant Number of B-cell Maturation Antigen (BCMA) Targeted Therapies in Pipeline is Expected to Boost Market Growth
  –  October 23, 2017
Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple ... GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd. Press ...
Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish
  –  September 27, 2017
Juno Therapeutics Inc (NASDAQ:JUNO), which is a biotech operator ... Something else to keep in mind: Juno has a robust pipeline. Note that the company has nine drugs in different trials (they range from Phase 1 to Phase 2). Right now, the lead candidate ...

Related News Coverage

Tweets

Featured Locations5